S 9977

may alleviate migranes; RN given refers to hydrochloride; structure given in first source

Also Known As:

1,3,7-trimethyl-8-(3-(4-diethylaminocarbonyl-1-piperazinyl)propyl)-3,7-dihydro-(1H)2,6-purinedione; S 9977-2; S-9977; S-9977-2; S9977

Networked: 2 relevant articles (0 outcomes, 0 trials/studies)

1.	Ganglion Cysts (Ganglion) 07/17/1992 - "In an attempt to investigate the role of cAMP-dependent phosphorylations on synaptic transmission at an Aplysia cholinergic buccal ganglion synapse, the effects of xanthine derivatives such as 3-isobutyl-1-methylxanthine (IBMX), which is well known to inhibit phosphodiesterase activity thereby promoting cAMP accumulation, and a novel xanthine derivative, S-9977-2 were evaluated. "
2.	Migraine Disorders (Migraine) 02/01/1992 - "These results are discussed in terms of the potential therapeutical usefulness of S9977 in the treatment of migraine." 02/01/1992 - "Effects of S9977 and dihydroergotamine in an animal experimental model for migraine."
3.	Hypotension (Low Blood Pressure) 02/01/1992 - "In contrast, S9977 (0.3, 1, 3 and 10 mg/kg, i.v.) caused a moderate hypotension and bradycardia. "
4.	Bradycardia 02/01/1992 - "In contrast, S9977 (0.3, 1, 3 and 10 mg/kg, i.v.) caused a moderate hypotension and bradycardia. "

1.	Xanthine
2.	Cholinergic Agents (Cholinergics)
3.	1-Methyl-3-isobutylxanthine (1 Methyl 3 isobutylxanthine)
4.	Phosphoric Diester Hydrolases (Phosphodiesterases)
5.	Dihydroergotamine (Agit)